Niacin has 54 known drug interactions based on U.S. FDA drug labeling data. 12 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Atorvastatin Calcium, Ezetimibe And Simvastatin, Fluvastatin. Patients taking Niacin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 54
- Major
- 12
- Moderate
- 41
Major (12)
- Niacin + Atorvastatin Calcium— Lipid-modifying doses (≥1 g/day) increase risk of adverse skeletal muscle effects. Use caution when coadministering.
- Niacin + Ezetimibe And Simvastatin— Lipid-modifying doses (≥1 g/day) increase risk of adverse skeletal muscle effects; not recommended for Chinese patients.
- Niacin + Fluvastatin— Lipid-modifying doses (≥1 g/day) of niacin increase risk of skeletal muscle effects. Fluvastatin dose reduction should b…
- Niacin + Fluvastatin Sodium— Lipid-modifying doses (≥1 g/day) may enhance risk of myopathy and rhabdomyolysis. Consider concomitant use only if benef…
- Niacin + Insulin Glargine— May decrease blood glucose lowering effect of LANTUS. Dosage increases and increased glucose monitoring may be required.
- Niacin + Lovastatin— Nicotinic acid at doses ≥1 g/day increases risk of myopathy when given with lovastatin.
- Niacin + Mao Inhibitors— Concomitant use may increase risk of skeletal muscle effects. See WARNINGS section for additional details.
- Niacin + Pitavastatin Calcium— Lipid-modifying doses of niacin (≥1 g/day) may increase the risk of myopathy and rhabdomyolysis with pitavastatin. Consi…
- Niacin + Pravastatin Sodium— Cases of myopathy and rhabdomyolysis observed with concomitant use. Monitor for signs and symptoms of myopathy.
- Niacin + Rosuvastatin Calcium— Lipid-modifying doses of niacin (≥1 g/day) with rosuvastatin increase risk of adverse skeletal muscle effects. Caution s…
- Niacin + Simvastatin— Niacin ≥1 g/day is not recommended with simvastatin in Chinese patients; increases risk of myopathy.
- Niacin + Statins— Caution should be used when prescribing niacin with statins as these agents can increase risk of myopathy/rhabdomyolysis…
Moderate (41)
- Niacin + Acarbose— Nicolinic acid produces hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Clos…
- Niacin + Acetylsalicylic Acid— Concomitant aspirin may decrease the metabolic clearance of nicotinic acid, though clinical relevance is unclear.
- Niacin + Adrenergic Blockers— Niacin may potentiate the effects of ganglionic blocking agents, resulting in postural hypotension.
- Niacin + Alcohol— Concomitant alcohol may increase side effects of flushing and pruritus and should be avoided at time of drug ingestion.
- Niacin + Alogliptin And Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control.
- Niacin + Amlodipine And Atorvastatin— Lipid-modifying doses of niacin increase risk of myopathy; consider risk/benefit of concomitant use.
- Niacin + Bile Acid Binding Resins— Bile acid sequestrants have high niacin-binding capacity; should be taken at least 4-6 hours before niacin extended-rele…
- Niacin + Dapagliflozin And Metformin Hydrochloride— Produces hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.
- Niacin + Empagliflozin, Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control; monitor closely.
- Niacin + Ertugliflozin And Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.
- Niacin + Glibenclamide— Nicotinic acid may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed f…
- Niacin + Glimepiride— May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
- Niacin + Glipizide— Nicotinic acid may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for lo…
- Niacin + Glipizide And Metformin Hydrochloride— Nicotinic acid may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed f…
- Niacin + Glyburide And Metformin Hydrochloride— Nicotinic acid tends to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.
- Niacin + Insulin Aspart Injection— May decrease the blood glucose lowering effect. Dose adjustment and increased glucose monitoring required.
- Niacin + Insulin Aspart-Szjj— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
- Niacin + Insulin Degludec— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Niacin + Insulin Degludec And Liraglutide— May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.
- Niacin + Insulin Detemir— May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be …
- Niacin + Insulin Glargine And Lixisenatide— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
- Niacin + Insulin Glargine-Aglr— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Niacin + Insulin Glargine-Yfgn— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Niacin + Insulin Glulisine— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
- Niacin + Insulin Human— May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.
- Niacin + Insulin Icodec-Abae— May decrease blood glucose lowering effect of Awiqli. Dose increases and increased glucose monitoring may be required.
- Niacin + Insulin Lispro— May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring required.
- Niacin + Insulin Lispro-Aabc— May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
- Niacin + Linagliptin And Metformin Hydrochloride— Nicotinic acid may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is r…
- Niacin + Metformin— Produces hyperglycemia and may lead to loss of glycemic control when used with metformin.
- Niacin + Metformin Er 500 Mg— May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose contro…
- Niacin + Metformin Hydrochloride— Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.
- Niacin + Metformin Hydrochloride Extended-Release Tablets— May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.
- Niacin + Metformin Hydrochloride Tablet— May produce hyperglycemia and lead to loss of glycemic control when used with metformin.
- Niacin + Nicotinamide— Other vitamins or nutritional supplements containing large doses of nicotinamide may potentiate the adverse effects of n…
- Niacin + Pitavastatin— Risk of myopathy and rhabdomyolysis may be increased with concomitant use of lipid-modifying doses (≥1 g/day) of niacin …
- Niacin + Pitavastatin Magnesium— Risk of myopathy and rhabdomyolysis may be increased with concomitant use of lipid-modifying doses (≥1 g/day) of niacin …
- Niacin + Repaglinide— May decrease blood glucose lowering effect of repaglinide. Dose increases and increased glucose monitoring may be requir…
- Niacin + Rosuvastatin— Lipid-modifying doses (≥1 g/day) of niacin increase risk of adverse skeletal muscle effects with rosuvastatin. Caution s…
- Niacin + Sitagliptin And Metformin Hydrochloride— May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.
- Niacin + Vasoactive Drugs— Niacin may potentiate the effects of vasoactive drugs, resulting in postural hypotension.